Erasca, Inc.

ERAS

NASDAQHealthcareBiotechnology

在 GoAI 中打开

前收盘价

US$17.63

+US$0.55 · +3.22%

8月21日 16:00 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

40/ 100

GoAI评分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

动量

Gaining

情绪

Mixed

风险韧性

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Jonathan E. Lim
上市以来: 2021年7月16日
雇员: 103

市场位置

日内区间

当前US$17.63，

US$17.26US$17.84

52周区间

当前US$17.63，

US$1.33US$24.28

开盘价: US$17.37
前收盘价: US$17.08
成交量: 244.54万; 0.41× 平均值
平均成交量: 590.06万; 日均成交量
市值: 61.2亿 USD
贝塔: 0.65; 市场参考 1
50天平均值: US$17.6598; 低于平均水平-0.17%
200天平均值: US$12.0856; 高于平均水平+45.88%

ERAS 消息

newsfilecorp.com2026年8月18日

ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain…

阅读源码

defenseworld.net2026年8月18日

81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB bought a new position in shares of Erasca, Inc. (NASDAQ: ERAS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional…

阅读源码

defenseworld.net2026年8月12日

Bank of America Corp DE Raises Position in Erasca, Inc. $ERAS

Bank of America Corp DE increased its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 89.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The…

阅读源码

globenewswire.com2026年8月11日

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination

阅读源码

newsfilecorp.com2026年8月10日

ERASCA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERAS

New York, New York--(Newsfile Corp. - August 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26,…

阅读源码